The novel beta 2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

Kraus, J.; Kraus, M.; Liu, N.; Besse, L.; Bader, J.; Geurink, P.P.; ... ; Driessen, C. (2015)

Article / Letter to editor

• Protease inhibitors
• Myeloma therapy
• Signal transduction
• Drug resistance

• All authors: Kraus, J.; Kraus, M.; Liu, N.; Besse, L.; Bader, J.; Geurink, P.P.; Bruin, G. de; Kisselev, A.F.; Overkleeft, H.; Driessen, C.
• Date: 2015-08-31
• Journal: Cancer Chemotherapy and Pharmacology
• Volume: 76
• Issue: 2
• Pages: 383 - 396
• DOI: doi:10.1007/s00280-015-2801-0